Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A novel topical formulation of 5-fluorouracil (5-FU) developed by Al-Azhar University for the treatment of localized stable vitiligo. This formulation utilizes effervescent technology, where gas bubbles (CO2) are generated upon hydration through a reaction between alkali salts and organic acids (such as citric or tartaric acid), enhancing the dissolution and potentially the skin penetration of the drug. While 5-FU is a well-known antimetabolite that inhibits thymidylate synthase to prevent DNA synthesis, its use in vitiligo leverages its side effect of hyperpigmentation, which is believed to result from the direct stimulation of melanocytes and an increase in melanosomes within keratinocytes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-fluorouracil effervescent powder.